NOVARTIS

A vaccines & diagnostics company needed a way to effectively manage its R&D pipeline and vaccine investment decisions.

CASE STUDY

THE CHALLENGE

Novartis sought to **optimize its acquisitions of new vaccines** to augment its existing R&D project portfolio.

Having the **right portfolio of vaccine development** projects across the various stages of its R&D pipeline is crucial.

THE SOLUTION

Automatically rolls up the complete portfolio of vaccines into a **multi-year, company-wide projection** of future performance.

Novartis can accurately **model** how each of the vaccines individually **progresses through its virtual lifecycle.**

THE RESULTS

✓ NOVARTIS IS NOW IN A POSITION TO **QUICKLY MODEL DIFFERENT** PORTFOLIO DEVELOPMENT **SCENARIOS**

✓ AN ASSUMPTIONS DASHBOARD ALLOWS USERS TO **EASILY MODIFY INPUT** PARAMETERS

✓ PIPELINE PERFORMANCE FORECASTS AND OPTIMIZED DRUG ACQUISITION SCHEDULES ARE **DELIVERED AS INTERACTIVE AND REAL-TIME WEB REPORTS** FOR GLOBAL ACCESS

"We are making strategic decisions that have long-term impacts on our business. Without Vanguard System, we would not have the visibility and analysis we need to make the right decisions."

Dr. Schwarzkopf, MBA, PhD
Senior Portfolio Manager, Novartis

Vanguard Software™ CORPORATION